henryee18
2021-11-05
Losses, price goes up, hit or exceed estimates price goes down… WTH?
Novavax Reports Q3 Loss, Misses Revenue Estimates
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
Michane
2021-11-05
Michane
Read the other news: "Novavax completes process for WHO emergency use approval of COVID-19 vaccine"
什么也没有了～
APP内打开
发表看法
5
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":846806810,"tweetId":"846806810","gmtCreate":1636071051505,"gmtModify":1636071064291,"author":{"id":3561088065415396,"authorId":3561088065415396,"authorIdStr":"3561088065415396","name":"henryee18","avatar":"https://static.tigerbbs.com/68e1124a4989ce380d6aa143a07b2620","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":862,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Losses, price goes up, hit or exceed estimates price goes down… WTH?</p></body></html>","htmlText":"<html><head></head><body><p>Losses, price goes up, hit or exceed estimates price goes down… WTH?</p></body></html>","text":"Losses, price goes up, hit or exceed estimates price goes down… WTH?","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846806810","repostId":1144097767,"repostType":4,"repost":{"id":"1144097767","pubTimestamp":1636070704,"share":"https://www.laohu8.com/m/news/1144097767?lang=&edition=full","pubTime":"2021-11-05 08:05","market":"us","language":"en","title":"Novavax Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1144097767","media":"Nasdaq","summary":"Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate","content":"<p>Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of -6.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $3.76 per share when it actually produced a loss of $4.75, delivering a surprise of -26.33%.</p>\n<p>Over the last four quarters, the company has not been able to surpass consensus EPS estimates.</p>\n<p>Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $178.84 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 41.71%. This compares to year-ago revenues of $157.02 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Novavax shares have added about 75.1% since the beginning of the year versus the S&P 500's gain of 24.1%.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Reports Q3 Loss, Misses Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Reports Q3 Loss, Misses Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 08:05 GMT+8 <a href=https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted...</p>\n\n<a href=\"https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.nasdaq.com/articles/novavax-nvax-reports-q3-loss-misses-revenue-estimates-2021-11-04","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144097767","content_text":"Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of -6.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $3.76 per share when it actually produced a loss of $4.75, delivering a surprise of -26.33%.\nOver the last four quarters, the company has not been able to surpass consensus EPS estimates.\nNovavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $178.84 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 41.71%. This compares to year-ago revenues of $157.02 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nNovavax shares have added about 75.1% since the beginning of the year versus the S&P 500's gain of 24.1%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":57,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":6459325,"gmtCreate":1636073242276,"gmtModify":1636079317372,"authorId":4091891386414570,"author":{"id":4091891386414570,"authorId":4091891386414570,"name":"Michane","avatar":"https://static.tigerbbs.com/e34d5ed60a80aa56ff9a8771c943602c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":846806810,"type":1,"supId":0,"prevId":0,"content":"Read the other news: \"Novavax completes process for WHO emergency use approval of COVID-19 vaccine\"","text":"Read the other news: \"Novavax completes process for WHO emergency use approval of COVID-19 vaccine\"","html":"Read the other news: \"Novavax completes process for WHO emergency use approval of COVID-19 vaccine\"","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/846806810"}
精彩评论